These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16930921)

  • 1. Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model.
    Smith PF; Tsuji B; Booker BM; Forrest A; Bajic S; Kelchlin P; Bhavnani SM; Jones RN; Ambrose PG
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):379-86. PubMed ID: 16930921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models.
    Ogden A; Kuhn M; Dority M; Buist S; Mehrens S; Zhu T; Xiao D; Miller JR; Hanna D
    Antimicrob Agents Chemother; 2012 Jan; 56(1):124-9. PubMed ID: 21986824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.
    Homma T; Hori T; Ohshiro M; Maki H; Yamano Y; Shimada J; Kuwahara S
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4300-5. PubMed ID: 20660692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.
    Pichichero ME; Doern GV; Kuti JL; Nicolau DP
    Paediatr Drugs; 2008; 10(6):391-7. PubMed ID: 18998749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.
    Nicolau DP; Sutherland CA; Arguedas A; Dagan R; Pichichero ME
    Paediatr Drugs; 2007; 9(2):119-23. PubMed ID: 17407367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
    Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
    J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic modeling for concentration-dependent bactericidal activity of a bicyclolide, modithromycin.
    Katsube T; Wajima T; Yamano Y; Yano Y
    J Pharm Sci; 2014 Apr; 103(4):1288-97. PubMed ID: 24523230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.
    Garrison MW; Malone CL; Eiland JE
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1545-7. PubMed ID: 8726036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment
    VanScoy BD; Lakota EA; Conde H; McCauley J; Friedrich L; Steenbergen JN; Ambrose PG; Bhavnani SM
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32284378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
    Doern GV; Vautour R
    Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation.
    Löwdin E; Cars O; Odenholt I
    Clin Microbiol Infect; 2002 Oct; 8(10):646-53. PubMed ID: 12390283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ; Marchillo K; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
    Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.